Akebia Therapeutics (AKBA): BTIG Sees 316% Price Potential - Potential in the CKD Market is Significantly Underestimated According to Experts!

Akebia Therapeutics Inc. (AKBA) is a biopharmaceutical company focused on the development and commercialization of therapies for patients with kidney diseases. In March 2024, Akebia received approval from the U.S. Food and Drug Administration (FDA) for Vafseo (Vadadustat) to treat anemia due to chronic kidney disease in adults who have been on dialysis for at least three months. The launch of Vafseo began in January 2025, with the medication being delivered to dialysis centers and authorized distributors starting January 9. The company has established...